Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
-- Record HEPLISAV-B® first quarter net product revenue of $65 million,
representing 36% year-over-year growth
-- Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected
in Q3 2025
-- New pandemic influenza adjuvant program and Lyme disease vaccine
programs planned to enter clinical development in 2025 and 2027,
respectively
-- Conference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., May 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.
"We started 2025 off strong, executing across our strategic growth initiatives, including delivering our highest first quarter net product revenue for HEPLISAV-B to date, putting us on track to achieve the top half of our full year guidance range. We are also excited to advance our pipeline leveraging our leading vaccine adjuvant technology, CpG 1018, with key clinical trial milestones this year for our shingles and plague vaccine programs, while further broadening our pipeline with new programs in pandemic influenza and Lyme disease," said Ryan Spencer, Chief Executive Officer of Dynavax. "We continue to focus on maintaining a disciplined approach to capital allocation, including executing over 85% of our share repurchase program to date, while evaluating external opportunities that leverage our infrastructure and capabilities to generate additional long-term growth for our shareholders and other stakeholders."
BUSINESS UPDATES
HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]
HEPLISAV-B vaccine is the first and only adult hepatitis B vaccine approved in the U.S., the European Union and the United Kingdom that enables series completion with only two doses in one month. In the U.S., hepatitis B vaccination is recommended for adults aged 19 to 59, and for adults aged 60 and older with risk factors, while adults aged 60 and older without known risk factors may also be vaccinated.
-- HEPLISAV-B achieved net product revenue of $65.0 million for the first
quarter of 2025, an increase of 36% compared to $47.8 million for the
first quarter of 2024.
-- HEPLISAV-B total estimated market share in the U.S. increased to
approximately 43%, compared to approximately 41% for the first quarter
2024.
-- Dynavax continues to expect the hepatitis B adult vaccine market in the
U.S. to expand to a peak of over $900 million in annual sales by 2030,
with HEPLISAV-B expected to achieve at least 60% total market share.
Additionally, Dynavax believes the HEPLISAV-B U.S. market opportunity
will remain substantial beyond 2030 due to the ongoing penetration of
the unvaccinated eligible adult population, observed revaccination
practices by healthcare providers, and continued gains in market share.
Clinical and Preclinical Pipeline
Dynavax is advancing a pipeline of differentiated product candidates that leverage its CpG 1018® adjuvant, which has demonstrated its ability to enhance the immune response with a favorable tolerability profile in a wide range of clinical trials and real-world commercial use.
Shingles Vaccine Program:
Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 years and older.
-- Dynavax is currently conducting Part 1 of a Phase 1/2 clinical trial, a
randomized, active-controlled, dose escalation, multicenter study, to
evaluate the safety, tolerability, and immunogenicity of Z-1018 compared
to Shingrix® in 441 healthy adults aged 50 to 69.
-- In the fourth quarter of 2024, Dynavax completed enrollment in Part 1,
and anticipates reporting top-line immunogenicity and safety data in the
third quarter of 2025.
-- Dynavax plans to advance the selected vaccine formulation and regimen
from Part 1 into Part 2 of the Phase 1/2 study in adults over age 70
years to generate clinical proof-of-concept in this key population, with
key endpoints including tolerability and immunogenicity comparisons to
Shingrix, ahead of advancement into a pivotal trial.
Plague Vaccine Program:
Dynavax is developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018 in collaboration with, and fully funded by, the U.S. Department of Defense (DoD).
-- In the fourth quarter of 2024, Dynavax and the DoD executed a new
agreement for approximately $30 million through the first half of 2027
to support additional clinical and manufacturing activities, including a
Phase 2 clinical trial expected to initiate in the third quarter of
2025.
Pandemic Influenza Adjuvant Program:
Dynavax is evaluating CpG 1018 in an adjuvanted H5N1 influenza vaccine as a proof-of-concept for its potential use with pandemic influenza vaccines.
-- Pandemic influenza remains one of the most persistent and unpredictable
global health threats. Vaccine adjuvants play an essential role in
pandemic preparedness, mostly due to their dose sparing capability, yet
despite their critical importance, the global supply of proven adjuvants
remains limited.
-- Leveraging its expertise and capabilities as a global supplier of CpG
1018 adjuvant for the development of multiple COVID-19 vaccines, Dynavax
intends to generate clinical proof-of-concept for CpG 1018-adjuvanted
pandemic influenza vaccines to support the potential commercial supply
of vaccine adjuvant needed for global pandemic preparedness and response
efforts.
-- In the second quarter of 2025, Dynavax expects to initiate a randomized,
active-controlled Phase 1/2 study to evaluate the safety and
immunogenicity of an investigational H5N1 influenza vaccine adjuvanted
with CpG 1018.
-- Part 1 of the Phase 1/2 trial is expected to enroll approximately 98
participants aged 18 to 49 years to receive either single-dose or
two-dose formulations of the investigational vaccine, with the intention
to select the optimal formulations of CpG 1018 adjuvant for Part 2 of
the Phase 1/2 trial.
Lyme Disease Vaccine Program:
Dynavax is developing an investigational multivalent protein subunit vaccine candidate adjuvanted with CpG 1018 for the prevention of Lyme disease, a bacterial infection that is the most common vector-borne illness in the Northern Hemisphere.
-- There are currently no approved human vaccines for Lyme disease, and
current vaccine candidates in clinical development require three-dose
primary series and annual boosters. Dynavax believes its investigational
Lyme disease vaccine adjuvanted with CpG 1018, which has a demonstrated
ability to amplify immune responses and improve durability of
protection, has the potential for a differentiated and best-in-class
vaccine profile.
-- Dynavax's Lyme disease vaccine candidate has progressed into
Investigational New Drug (IND)-enabling studies, with plans to initiate
clinical development in 2027.
HEPLISAV-B for Adults on Hemodialysis:
-- Dynavax plans to conduct an observational retrospective cohort study to
support its sBLA filing for a HEPLISAV-B® vaccine regimen for adults on
hemodialysis. In the first quarter of 2025, Dynavax received feedback
from the U.S. Food and Drug Administration (FDA) that its proposed
patient database may be acceptable for the observational retrospective
cohort study, and Dynavax is engaging with the FDA to finalize the study
protocol.
FIRST QUARTER 2025 FINANCIAL HIGHLIGHTS
-- Total revenues were $68.2 million for the first quarter of 2025, a 34%
increase compared to $50.8 million for the first quarter of 2024.
-- HEPLISAV-B net product revenue was $65.0 million for the first quarter
of 2025, a 36% increase compared to $47.8 million for the first quarter
of 2024.
-- Cost of sales - product for HEPLISAV-B were $13.8 million for the first
quarter of 2025, compared to $11.0 million for the first quarter of
2024.
-- Research and development expenses (R&D) were $19.4 million for the first
quarter of 2025, compared to $13.5 million for the first quarter of
2024.
-- Selling, general, and administrative expenses (SG&A) were $47.7 million
for the first quarter of 2025, compared to $44.1 million for the first
quarter of 2024.
-- Bad debt expense: During the first quarter of 2025, Dynavax recorded an
allowance for doubtful accounts of $11.0 million relating to the
adjuvant commercial supply agreement with Clover Biopharmaceuticals.
This bad debt expense reflects an assessed heightened credit risk
associated with Clover, primarily due to Gavi, the Vaccine Alliance's
termination of its advanced purchase agreement, coupled with Clover's
recently reported write-down of its CpG 1018 adjuvant and liquidity
position as of December 31, 2024.
-- GAAP net loss was $96.1 million, or a net loss of $0.77 per share (basic
and diluted) for the first quarter of 2025, compared to GAAP net loss of
$8.7 million, or a net loss of $0.07 per share (basic and diluted) for
the first quarter of 2024. The net loss in the first quarter of 2025 was
primarily due to a loss on the extinguishment of debt relating to the
convertible debt refinancing in March 2025.
-- Adjusted EBITDA* was negative $4.4 million for the first quarter of
2025, compared to negative $6.8 million for the first quarter of 2024.
-- Cash, cash equivalents and marketable securities were $661.3 million as
of March 31, 2025, compared to $713.8 million as of December 31, 2024.
-- Convertible debt refinancing: In March 2025, Dynavax refinanced a
majority of its outstanding convertible senior notes, which extended the
maturity date of most of its existing debt, lowered its overall cost of
capital through improved terms, and reduced basic and diluted shares
outstanding.
-- Share repurchase program: In November 2024, Dynavax announced a $200
million share repurchase program authorized by its Board of Directors,
including $100 million repurchased through an accelerated share
repurchase program, which was completed in the first quarter of 2025. As
of May 5, 2025, Dynavax has repurchased $172 million worth of common
stock under the $200 million share repurchase program, and anticipates
completing the remaining repurchases by the end of 2025.
FULL YEAR 2025 FINANCIAL GUIDANCE
Dynavax is reaffirming its full year 2025 financial guidance, based on its current operating plan:
-- HEPLISAV-B net product revenue is expected in the range of $305 to $325
million.
-- Adjusted EBITDA* is expected to be at least $75 million.
* Non-GAAP financial measure. Please refer to the "Non-GAAP Financial Measures" section for details regarding this measure.
Conference Call and Webcast Information
Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of Dynavax's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
WHAT IS HEPLISAV-B?
HEPLISAV-B is a shot given to adults 18 years of age and older to help prevent infection caused by the hepatitis B virus. HEPLISAV-B is usually given in the arm muscle. HEPLISAV-B is given in 2 doses, 1 month apart, by a healthcare provider.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
There are no adequate and well-controlled studies of HEPLISAV-B in pregnant individuals. Available data, primarily in individuals who received one dose of HEPLISAV-B in the 28 days prior to or during pregnancy, do not suggest an increased risk of major birth defects and miscarriage.
It is not known whether HEPLISAV-B is excreted in human milk.
Data are not available to assess the effects of HEPLISAV-B on the breastfed infant or on milk production/excretion.
Vaccination with HEPLISAV-B may not result in protection of all vaccine recipients.
Talk to your healthcare provider to determine if HEPLISAV-B is right for you.
Please see full Prescribing Information
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Dynavax has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about Dynavax's marketed products and development pipeline, visit www.dynavax.com.
Non-GAAP Financial Measures
To supplement financial results presented on a GAAP basis, Dynavax has included information about adjusted EBITDA, a non-GAAP financial measure. Dynavax believes the presentation of this non-GAAP financial measure, when viewed with its results under GAAP and the accompanying reconciliation, provide analysts, investors and other third parties with insights into how Dynavax evaluates normal operational activities, including its ability to generate cash from operations, on a comparable year-over-year basis, and manage its budgeting and forecasting.
In quarterly and annual reports, earnings press releases and conference calls, Dynavax may discuss Adjusted EBITDA to supplement its consolidated financial statements presented on a GAAP basis.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in Dynavax's business but do not represent ongoing operations, including loss on debt extinguishment and proxy contest costs. Adjusted EBITDA, as used by Dynavax, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as:
-- adjusted EBITDA excludes depreciation and amortization, and, although
these are non-cash expenses, the assets being depreciated or amortized
may have to be replaced in the future, the cash requirements for which
are not reflected in adjusted EBITDA;
-- adjusted EBITDA does not reflect changes in, or cash requirements for,
working capital needs;
-- adjusted EBITDA does not reflect the benefit from or provision for
income taxes or the cash requirements to pay taxes;
-- adjusted EBITDA does not reflect historical cash expenditures or future
requirements for capital expenditures or contractual commitments;
-- Dynavax excludes stock-based compensation expense from adjusted EBITDA
although: (i) it has been, and will continue to be for the foreseeable
future, a significant recurring expense for its business and an
important part of its compensation strategy; and (ii) if Dynavax did not
pay out a portion of its compensation in the form of stock-based
compensation, the cash salary expense included in operating expenses
would be higher, which would affect its cash position;
-- From time to time, Dynavax may exclude other expenses that are episodic
in nature and do not directly correlate to the cost of operating its
business on an ongoing basis, such as loss on debt extinguishment and
proxy contest costs.
Reconciliation of each historical non-GAAP financial measure to Adjusted EBITDA can be found in the table accompanying this press release. The Company has not provided a reconciliation of its full-year 2025 guidance for Adjusted EBITDA to the most directly comparable forward-looking GAAP measures because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, income tax expense or provision for income taxes. These items are uncertain and depend on various factors that are outside of the Company's control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income for the guidance period. A reconciliation of Adjusted EBITDA would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "will," "may," "plan," "potential," "would" and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding Dynavax's expected financial results for the quarter ended March 31, 2025, expectations regarding its future growth and long-term performance, extent and timing of market growth and market share beyond 2030, the timing of IND filings, initiation and completion of clinical studies, expected timing for data readouts, and interaction with regulators. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Dynavax's business, including, the risk that market size or actual demand for its products may differ from its expectations, risks relating to its ability to commercialize and supply HEPLISAV-B, risks related to the timing of completion and results of current clinical studies, risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018 adjuvant, as well as other risks detailed in the "Risk Factors" section of its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 and periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in its other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and Dynavax undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in its current periodic reports with the SEC.
Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the U.S. Government and shall not be used for advertising or product endorsement purposes.
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
March 31,
2025 2024
Revenues:
Product revenue, net $64,959 $47,845
Other revenue 3,205 2,945
Total revenues 68,164 50,790
Operating expenses:
Cost of sales - product 13,769 10,966
Research and development 19,377 13,528
Selling, general and administrative 47,678 44,065
Bad debt expense 10,970
Total operating expenses 91,794 68,559
Loss from operations (23,630) (17,769)
Other income (expense):
Interest income 7,739 9,468
Interest expense (1,692) (1,695)
Sublease income (expense) (Note 5) 2,226 (1,602)
Loss on debt extinguishment (82,095)
Other (loss) income (423) 101
Net loss before income taxes (97,875) (11,497)
Benefit from income taxes 1,776 2,776
Net loss $(96,099) $(8,721)
Net loss per share attributable to common stockholders
Basic $(0.77) $(0.07)
Diluted $(0.77) $(0.07)
Weighted-average shares used in computing net loss per share attributable
to common stockholders:
Basic 124,871 130,200
Diluted 124,871 130,200
DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)
March 31, December 31,
2025 2024
Assets
Cash, cash equivalents and marketable securities $661,336 $713,834
Inventories 74,403 70,054
Other current assets 80,231 65,053
Total current assets 815,970 848,941
Total non-current assets 129,958 137,315
Total assets $945,928 $986,256
Liabilities and stockholders' equity
Total current liabilities $68,379 $78,634
Total long-term liabilities 346,608 310,823
Stockholders' equity 530,941 596,799
Total liabilities and stockholders' equity $945,928 $986,256
DYNAVAX TECHNOLOGIES CORPORATION
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(In thousands)
(Unaudited)
Three Months Ended
March 31,
2025 2024
GAAP net loss $(96,099) $(8,721)
Adjustments:
Depreciation & amortization 374 375
Interest income (7,739) (9,468)
Interest expense 1,692 1,695
Benefit from income taxes (1,776) (2,776)
Total adjustments (7,449) (10,174)
EBITDA (103,548) (18,895)
Stock-based compensation 13,449 12,144
Loss on debt extinguishment 82,095
Proxy contest costs 3,648
Adjusted EBITDA $(4,356) $(6,751)
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-reports-first-quarter-2025-financial-results-and-announces-new-pipeline-programs-302447589.html
SOURCE Dynavax Technologies
